Telomir Pharmaceuticals, Inc. Common Stock (TELO) — Financial statements
Income statement, balance sheet, and cash flow for Telomir Pharmaceuticals, Inc. Common Stock — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 2↑9.0% | 2↑42.0% | 2↑88.9% | 0.83↑558.7% | 0.13 | |
| General & Administrative Expenses | 8↓15.9% | 10↑1505.5% | 0.60↑2766.1% | 0.02↑79.9% | 0.01 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 8↓15.9% | 10↑1505.5% | 0.60↑2766.1% | 0.02↑79.9% | 0.01 | |
| Other Expenses | 0.00↓100.0% | 0.37↓79.0% | 2 | 0.00 | 0.00 | |
| Operating Expenses | 11↓13.9% | 12↑210.6% | 4↑361.5% | 0.85↑518.4% | 0.14 | |
| Total Costs & Expenses | 11↓13.9% | 12↑210.6% | 4↑361.5% | 0.85↑518.4% | 0.14 | |
| Operating Results | ||||||
| Operating Income | -11↑13.9% | -12↓210.6% | -4↓361.5% | -0.85↓518.4% | -0.14 | |
| Depreciation & Amortization | 0.00↓100.0% | 12 | 0.00↓100.0% | 0.85↑518.4% | 0.14 | |
| EBITDA | -11↓22055.9% | 0.05↑100.4% | -11 | 0.00 | 0.00 | |
| EBIT | -11↑13.6% | -12↓6.7% | -11↓1238.0% | -0.85↓518.4% | -0.14 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.13↓97.1% | 4↑367.0% | -2 | 0.00 | 0.00 | |
| Interest Income | 0.13↑161.8% | 0.05 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00↑100.0% | -4↓364.1% | 2 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -0.05↓100.6% | 7 | 0.00 | 0.00 | |
| Other Income / Expenses | 0.13↑102.9% | -4↑53.0% | -9 | 0.00 | 0.00 | |
| Income Before Tax | -10↑37.0% | -17↓26.5% | -13↓1430.4% | -0.85↓518.4% | -0.14 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -10↑37.0% | -17↓26.5% | -13↓1430.4% | -0.85↓518.4% | -0.14 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -10↑37.0% | -17↓26.5% | -13↓1430.4% | -0.85↓518.4% | -0.14 | |
| Bottom-Line Net Income | -10↑37.0% | -17↓26.5% | -13↓1430.4% | -0.85↓518.4% | -0.14 | |
| EPS (Basic) | -0.33↑41.1% | -0.56↓27.3% | -0.44↓1427.8% | -0.03↓512.8% | -0.00 | |
| EPS (Diluted) | -0.33↑41.1% | -0.56↓27.3% | -0.44↓1427.8% | -0.03↓512.8% | -0.00 | |
| Weighted Average Shares | 32↑7.2% | 30↓0.2% | 30↑0.0% | 30↑0.0% | 30 | |
| Weighted Average Diluted Shares | 32↑7.2% | 30↓0.2% | 30↑0.0% | 30↑0.0% | 30 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.